Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Kelsey Research Foundation

Neither a doctor nor a teaching hospital

Research payments

$2,025,488

227 payments

Through program year 2025, Kelsey Research Foundation is reported as receiving $2,025,488 in research payments, across 227 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,011,444 55
2024 Research $329,251 38
2023 Research $247,721 23
2022 Research $91,822 18
2021 Research $51,274 27
2020 Research $99,756 26
2019 Research $194,221 40

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $674,604 114 payments
  2. Eli Lilly and Company $417,677 11 payments
  3. AstraZeneca Pharmaceuticals LP $291,257 2 payments
  4. Celgene Corporation $123,645 3 payments
  5. Cleerly, Inc. $97,671 23 payments
  6. Smith+Nephew, Inc. $96,037 11 payments
  7. Gilead Sciences, Inc. $92,287 24 payments
  8. Merck Sharp & Dohme Corporation $70,157 2 payments
  9. Genentech, Inc. $34,439 5 payments
  10. Novartis Pharmaceuticals Corporation $28,969 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Talapro3 A Phase 3 Randomized Doubleblind Study of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide in Men With DDR Gene Mutated Metastatic Castrationsensitive Prostate Cancer $599,136 71 payments
  2. Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (Trailblazer-Real US) $295,604 4 payments
  3. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $271,308 1 payment
  4. A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) $106,079 3 payments
  5. A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) $103,716 5 payments
  6. Transform $97,671 23 payments
  7. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $75,468 43 payments
  8. Biosure RG Inteference Screw PMCFU $59,499 5 payments
  9. Safety and Performance of the BIOSURE REGENESORB Interference Screw in Knee Ligament Repair and Reconstructions $36,538 6 payments
  10. A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl $35,345 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record